Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Major BREAKOUT COMING
Take a look at this Ask :
http://www.otcmarkets.com/stock/pmbs/quote
NITE 0.5101 2500 13:10
ETMM 0.60 2500 13:22
DOMS 0.85 2500 11/12
HDSN 1.50 500 10:39
VFIN 1.70 500 11/16
Get in now before its too late folks !
THIS IS THE ASK SIDE:
NITE 0.50 5000
AUTO 0.50 5000
HDSN 0.75 2500
DOMS 0.85 2500
GET IN NOW BEFORE ITS TOO LATE .
Last chance to load up cheap shares under 1 dollar
THIS IS THE ASK SIDE:
NITE 0.50 5000
AUTO 0.50 5000
HDSN 0.75 2500
DOMS 0.85 2500
GET IN NOW BEFORE ITS TOO LATE .
Drug launch news is around the corner
RALLLYYYYYYYYYYYYYYYYYYYYYYY
PMBS.PK EXPLODING .. THIS IS JUST THE BEGINNING
3 Drugs to enter the market in 1Q 2011 . Market cap of 4 Mil is really a big joke .
ENJOY THE RIDE .
RUNUP HAS JUST BEGUN
GET IN NOW BEFORE ITS TOO LATE EOM .
Please click link and look at ASK !!
http://www.otcmarkets.com/stock/pmbs/quote
ASK:
VERT 0.275 5000 << Last shares then jump to 49c
HDSN 0.49 5000 <<
GET IN NOW OR MISS THE BIG MONSTER OPPORTUNITY ! GL
Please click link and look at ASK !!
http://www.otcmarkets.com/stock/pmbs/quote
ASK:
VERT 0.275 5000 << Last shares then jump to 49c
HDSN 0.49 5000 <<
GET IN NOW OR MISS THE BIG OPPORTUNITY !
MAJOR BREAKOUT COMING ANY TIME NOW :::::
http://www.otcmarkets.com/stock/pmbs/quote
THIS IS THE ASK:( COULD EXPLODE TODAY )
NITE 0.34 5000 12/22 <<
DOMS 0.85 2500 11/12 <<
HDSN 1.10 500 12/22
VFIN 1.70 500 11/16
3 Major Drugs to be launched into Market in 1Q11 .Market cap of 5 million$ is a big joke .This undiscovered low float stock will explode like VRML or HGSI .
Puramed (PMBS.PK)
Market Cap: 5 M$
Cash : 5 M$ agreement with Lincoln capital Fund (june 2010)
Price 0,34 $
Shares Out: 14.1 M ...( 9 million shares held by Directors )
Low Float : 5 M
How many products does PuraMed BioScience have in progress?
LipiGesic M for the relief of migraine headaches is the first PuraMed product that will be introduced to the market. Following its entrance into the market, two other products, LipiGesic PM for insomnia and LipiGesic H for tension headaches, will be developed and introduced. There are also product formulations for relief from canker sores, restless-leg syndrome, nighttime-reflux disorders, smoking cessation, and weight loss that will soon follow.
PuraMed was established to capture two unique opportunities. The first is to build a substantial and profitable business, rapidly, beginning with three products developed by its founders: LipiGesic™ M (for acute relief of migraine headaches), LipiGesic™ H(for acute relief of tension headaches) and PuraMed™ PM (for insomnia). Each of these is effective and addresses a very large OTC consumer market, collectively well over $2 billion in the U.S. Each product will be unique in its class.
The second, longer term, opportunity is to establish a leadership position in the highly fragmented OTC natural and alternative health remedy market by introducing a “new kind of product line.” Our product line will consist of ‘alternative’ remedies for common ailments, marketed to the masses. Most consumers want products that are, first of all, effective and safe. By applying hard science to ‘natural’ products, management believes it is possible to build a line wherein each product delivers better performance with fewer side effects than its chemical counterparts. With effective marketing, these products will be embraced by the majority, many of whom prefer ‘natural’ alternatives, provided there is no need to sacrifice performance or convenience.
PuraMed BioScience, Inc will enter the OTC (Over-The-Counter) medicine marketplace by employing direct to consumer marketing and applying broad retail distribution and effective marketing to several unique products now developed and known to be effective. The company intends to launch its first two retail products within six months and leverage that success to ultimately become a leader in the OTC medicine marketplace.
MAJOR BREAKOUT COMING ANY TIME NOW :::::
http://www.otcmarkets.com/stock/pmbs/quote
THIS IS THE ASK:( COULD EXPLODE TODAY )
NITE 0.34 5000 12/22 <<
DOMS 0.85 2500 11/12 <<
HDSN 1.10 500 12/22
VFIN 1.70 500 11/16
3 Major Drugs to be launched into Market in 1Q11 .Market cap of 5 million$ is a big joke .This undiscovered low float stock will explode like VRML or HGSI .
Puramed (PMBS.PK)
Market Cap: 5 M$
Cash : 5 M$ agreement with Lincoln capital Fund (june 2010)
Price 0,34 $
Shares Out: 14.1 M ...( 9 million shares held by Directors )
Low Float : 5 M
How many products does PuraMed BioScience have in progress?
LipiGesic M for the relief of migraine headaches is the first PuraMed product that will be introduced to the market. Following its entrance into the market, two other products, LipiGesic PM for insomnia and LipiGesic H for tension headaches, will be developed and introduced. There are also product formulations for relief from canker sores, restless-leg syndrome, nighttime-reflux disorders, smoking cessation, and weight loss that will soon follow.
PuraMed was established to capture two unique opportunities. The first is to build a substantial and profitable business, rapidly, beginning with three products developed by its founders: LipiGesic™ M (for acute relief of migraine headaches), LipiGesic™ H(for acute relief of tension headaches) and PuraMed™ PM (for insomnia). Each of these is effective and addresses a very large OTC consumer market, collectively well over $2 billion in the U.S. Each product will be unique in its class.
The second, longer term, opportunity is to establish a leadership position in the highly fragmented OTC natural and alternative health remedy market by introducing a “new kind of product line.” Our product line will consist of ‘alternative’ remedies for common ailments, marketed to the masses. Most consumers want products that are, first of all, effective and safe. By applying hard science to ‘natural’ products, management believes it is possible to build a line wherein each product delivers better performance with fewer side effects than its chemical counterparts. With effective marketing, these products will be embraced by the majority, many of whom prefer ‘natural’ alternatives, provided there is no need to sacrifice performance or convenience.
PuraMed BioScience, Inc will enter the OTC (Over-The-Counter) medicine marketplace by employing direct to consumer marketing and applying broad retail distribution and effective marketing to several unique products now developed and known to be effective. The company intends to launch its first two retail products within six months and leverage that success to ultimately become a leader in the OTC medicine marketplace.
THE SAME MANAGEMENT WILL BRING THE LIPIGESIC PRODUCTS TO MARKET NEXT Q .DO YOU KNOW WHAT WILL HAPPEN WITH THE SHARE PRICE IF THEY REACH THE SAME NUMBERS WITH LIPIGESIC ??? BOOM TO ORBIT !!
MARKET CAP : $5 MIL
Product development and design packaging of all PuraMed products have been conducted entirely by the Company's two principal officers, Russell Mitchell and James Higgins: Messrs. Mitchell and Higgins have extensive and lengthy experience in new product development and marketing of non-prescription medical products and nutritional supplements and the many varied promotional activities involved in their marketing rollouts. For example, Mitchell Health Technologies served as the master broker for the launch of Quigley Corp's "Cold-Eeze" treatment for common colds, which within 18 months exceeded $70 million in annual wholesale revenues. The Company considers the long and successful professional involvement of its management team in our industry to be a valuable asset to draw upon to achieve the future growth and profitability anticipated by the Company.
THE SAME MANAGEMENT WILL BRING THE LIPIGESIC PRODUCTS TO MARKET NEXT Q .DO YOU KNOW WHAT WILL HAPPEN WITH THE SHARE PRICE IF THEY REACH THE SAME NUMBERS WITH LIPIGESIC ??? BOOM TO ORBIT !!
Product development and design packaging of all PuraMed products have been conducted entirely by the Company's two principal officers, Russell Mitchell and James Higgins: Messrs. Mitchell and Higgins have extensive and lengthy experience in new product development and marketing of non-prescription medical products and nutritional supplements and the many varied promotional activities involved in their marketing rollouts. For example, Mitchell Health Technologies served as the master broker for the launch of Quigley Corp's "Cold-Eeze" treatment for common colds, which within 18 months exceeded $70 million in annual wholesale revenues. The Company considers the long and successful professional involvement of its management team in our industry to be a valuable asset to draw upon to achieve the future growth and profitability anticipated by the Company.
http://www.otcmarkets.com/stock/pmbs/quote
Take a look at this ASK .. This stock is ready to take off .
AUTO 0.35 5000
NITE 0.40 5000
HDSN 0.402 5000
DOMS 0.85 2500
VFIN 1.70 500
Get in now before the stock gets discovered
http://www.otcmarkets.com/stock/pmbs/quote
Take a look at this ASK .. This stock is ready to take off .
AUTO 0.35 5000
NITE 0.40 5000
HDSN 0.402 5000
DOMS 0.85 2500
VFIN 1.70 500
Get in now before the stock gets discovered
LOAD UP THE TRUCK WITH CHEAP SHARES
MARKET LAUNCH NEWS FOR THEIR MIRGAINE DRUG COMING ANY DAY NOW
LOAD UP BEFORE THE NEWS IS OUT
MARKET LAUNCH NEWS FOR THEIR MIGRAINE DRUG COMING ANY DAY NOW
Buy 10k shares and this stock will move over 1 dollar . Pmbs is the next VRML .
Look at Ask :
HDSN 0.51 2500 12/21
NITE 0.55 2500 12/21
DOMS 0.85 2500 11/12
VFIN 1.70 500 11/16
3 Big Drugs to be launched on the Market in 1Q11 .Market cap of 7 million$ is a big joke .
Get in now before the stock gets Discovered !!! Easy money at this level .
Puramed (PMBS.PK)
Market Cap: 7,2 M$
Cash : 5 M$ agreement with Lincoln capital Fund (june 2010)
Price 0,51 $
Shares Out: 14.1 M ...( 12 million shares held by insiders )
Low Float : 5 M
How many products does PuraMed BioScience have in progress?
LipiGesic M for the relief of migraine headaches is the first PuraMed product that will be introduced to the market. Following its entrance into the market, two other products, LipiGesic PM for insomnia and LipiGesic H for tension headaches, will be developed and introduced. There are also product formulations for relief from canker sores, restless-leg syndrome, nighttime-reflux disorders, smoking cessation, and weight loss that will soon follow.
PuraMed was established to capture two unique opportunities. The first is to build a substantial and profitable business, rapidly, beginning with three products developed by its founders: LipiGesic™ M (for acute relief of migraine headaches), LipiGesic™ H(for acute relief of tension headaches) and PuraMed™ PM (for insomnia). Each of these is effective and addresses a very large OTC consumer market, collectively well over $2 billion in the U.S. Each product will be unique in its class.
The second, longer term, opportunity is to establish a leadership position in the highly fragmented OTC natural and alternative health remedy market by introducing a “new kind of product line.” Our product line will consist of ‘alternative’ remedies for common ailments, marketed to the masses. Most consumers want products that are, first of all, effective and safe. By applying hard science to ‘natural’ products, management believes it is possible to build a line wherein each product delivers better performance with fewer side effects than its chemical counterparts. With effective marketing, these products will be embraced by the majority, many of whom prefer ‘natural’ alternatives, provided there is no need to sacrifice performance or convenience.
PuraMed BioScience, Inc will enter the OTC (Over-The-Counter) medicine marketplace by employing direct to consumer marketing and applying broad retail distribution and effective marketing to several unique products now developed and known to be effective. The company intends to launch its first two retail products within six months and leverage that success to ultimately become a leader in the OTC medicine marketplace.
If we all shareholders protect our shares there will be soon no shares available for short means our low float stock will move like a Hurricane .
PMBS could reach 7-10 dollar if we do this .Thank you for your Support .
http://www.contracts-for-difference.com/Borrowing-lending-shares.html
Q.: What can you do to prevent your shares holdings from being shorted?
A: Now what can the average personal investor do to stop their own shares being shorted, as believe me your own broker, if approached, WILL sell your own shares that they hold on your behalf as a nominee account.
There are two things you can do, the first is to certificate them but this is not obviously to everyone’s advantage but the alternative solution is simple. All you do is to phone your broker and put an order in saying that you wish to place your shares for sale at, for arguments sake, double today’s price. As they are 'on order' they cannot be lent out by your broker and in turn you are reducing the amount of 'free shares' out there that can be used for shorting purposes. And don't forget to move your limit order up when the price starts to recover, then, that way your shares can't be shorted - not much but helps :D.
Although an individual personal investor will not normally have enough shares to halt a concerted shorting attack, if a large number of holders did this it would reduce the overall amount of shares that they could get their hands on.
In my opinion well worth doing if not only for the knowledge that your own shares cannot and will not be used in a short attack against the very share that you own.
RALLYYYYYYYYYYYYYYYYYYYYYYYYYYYYYY
Load up before its too late ..YIPPIIIIII
ASK now at 51c
HDSN 0.51 2500 15:35
NITE 0.55 2500 15:08
AUTO 0.68 2500 15:01
DOMS 0.85 2500 11/12
VFIN 1.70 500 11/16
RALLLYYYYYYYYYYYYYYYYYYYYYYYYYY
PMBS.PK is flying away woohooo
Up she goes baby
http://ih.advfn.com/p.php?pid=webchart&symbol=PMBS&period=0&size=19&volume=1
looak at ask LOL this stock will explode with a few buyers .
MPID Ask Price Size Date/Time
AUTO 0.23 5000 14:31
HDSN 0.35 5000 12:11
NITE 0.42 5000 11:50
DOMS 0.85 2500 11/12
VFIN 1.70 500 11/16
Up she goes
see you at 1 dollar by friday
TIME TO BUY PMBS ...LOTS OF NEWS COMING
Puramed will launch 3 big drugs in 1Q 2011.
If you like EDAP you will like PMBS too .Market cap of 2,8 million$ is massive undervalued . This stock is under Radar .
Get in now before the stock gets Discovered !!! Easy money at this level .
Puramed (PMBS.PK)
Market Cap: 2,8 M$
Cash : 5 M$ agreement http://puramedbioscience.com/PR/2010_PuraMed_PR-Jun%201%202010.pdf
Price 0,19 $
Shares Out: 14.1 M ...( 9 million shares held by insiders )
Low Float : 5 M
A MUST READ ......
http://www.puramedbioscience.com/PuraMed%20Corp%20Profile-4.2010.pdf
Only a few shares available below 1 Dollar
http://www.otcmarkets.com/stock/pmbs/quote
Why Puramed Bioscience Inc. (PMBS.OB) Should Be On Your Radar
PuraMed Bioscience, Inc. is a pharmaceutical company focused on developing and marketing a line of new, non-prescription medicines. These products target major consumer health needs, including the treatment of headaches, insomnia, and general pain. The company aims launch its first retail products within six months, and then leverage that success to become a leader in the Over-the-Counter (OTC) medicine marketplace.
Although PuraMed Bioscience is entering into a competitive market, the company’s products promise to bring innovation to the industry, allowing for faster absorption into the blood stream, greater effectiveness, fewer side effects, and lower dosage requirements. The first three products the company plans to introduce include: LipiGesic M™ (for acute relief of migraine headaches), LipiGesic H™ (for acute relief of tension headaches) and LipiGesic PM™ (for insomnia).
PuraMed is already sufficiently funded via private funding and ready to move forward with the execution of its comprehensive business plan. Recently BrokerBank analyst Philip Wright, CFA initiated investment coverage of the company and has rated the company as a “speculative buy”. Wright praised the company for running on a lean basis by keeping salaries reasonable and office overhead costs extremely low.
The share structure of the stock is also attractive with only 14,129,246 shares of common stock outstanding as of last month. PuraMed is also a fully reporting company, meaning the company must be audited by a PCAOB registered public accounting firm and must comply with the requirements of Sarbanes-Oxley. These requirements allow for greater transparency and the ability to attract a larger investor audience, subsequently enhancing shareholder value and providing greater access to capital for further growth.
With a management team bringing more than 80 years of combined industry experience, a product line addressing major healthcare needs with many competitive advantages, and a well thought-out business plan, this company is well on its way to success in the multi-billion dollar OTC medicine market. Continue to watch this company as it strives to dramatically improve the quality of life for millions of Americans.
Puramed will launch 3 big drugs in 1Q 2011.
If you like EDAP you will like PMBS too .Market cap of 2,8 million$ is massive undervalued . This stock is under Radar .
Get in now before the stock gets Discovered !!! Easy money at this level .
Puramed (PMBS.PK)
Market Cap: 2,8 M$
Cash : 5 M$ agreement http://puramedbioscience.com/PR/2010_PuraMed_PR-Jun%201%202010.pdf
Price 0,19 $
Shares Out: 14.1 M ...( 9 million shares held by insiders )
Low Float : 5 M
A MUST READ ......
http://www.puramedbioscience.com/PuraMed%20Corp%20Profile-4.2010.pdf
Only a few shares available below 1 Dollar
http://www.otcmarkets.com/stock/pmbs/quote
Why Puramed Bioscience Inc. (PMBS.OB) Should Be On Your Radar
PuraMed Bioscience, Inc. is a pharmaceutical company focused on developing and marketing a line of new, non-prescription medicines. These products target major consumer health needs, including the treatment of headaches, insomnia, and general pain. The company aims launch its first retail products within six months, and then leverage that success to become a leader in the Over-the-Counter (OTC) medicine marketplace.
Although PuraMed Bioscience is entering into a competitive market, the company’s products promise to bring innovation to the industry, allowing for faster absorption into the blood stream, greater effectiveness, fewer side effects, and lower dosage requirements. The first three products the company plans to introduce include: LipiGesic M™ (for acute relief of migraine headaches), LipiGesic H™ (for acute relief of tension headaches) and LipiGesic PM™ (for insomnia).
PuraMed is already sufficiently funded via private funding and ready to move forward with the execution of its comprehensive business plan. Recently BrokerBank analyst Philip Wright, CFA initiated investment coverage of the company and has rated the company as a “speculative buy”. Wright praised the company for running on a lean basis by keeping salaries reasonable and office overhead costs extremely low.
The share structure of the stock is also attractive with only 14,129,246 shares of common stock outstanding as of last month. PuraMed is also a fully reporting company, meaning the company must be audited by a PCAOB registered public accounting firm and must comply with the requirements of Sarbanes-Oxley. These requirements allow for greater transparency and the ability to attract a larger investor audience, subsequently enhancing shareholder value and providing greater access to capital for further growth.
With a management team bringing more than 80 years of combined industry experience, a product line addressing major healthcare needs with many competitive advantages, and a well thought-out business plan, this company is well on its way to success in the multi-billion dollar OTC medicine market. Continue to watch this company as it strives to dramatically improve the quality of life for millions of Americans.
Double digits coming
Marc Oczachowski, EDAP’s chief executive officer, continued, “Therapeutic ultrasound is gradually gaining ground in cancer treatment approach. We clearly see a growing interest in minimally invasive focal therapies for cancer tumors. Our 20 years expertise in the treatment of localized prostate cancer using HIFU has long been demonstrated and we are excited to further participate in the development of such new projects aiming at improving cancer drug delivery. While we expand our expertise in HIFU to further applications, we remain fully focused on developing our HIFU technology and adapt it to the current focal therapy trend to treat prostate cancers. We believe that the focal therapy approach represents a unique opportunity for Ablatherm HIFU to become the gold standard of treatment for prostate cancer.”
WHY EDAP IS A MUST BUY !!
Hifu: A New Prostate Treatment
A Twin Cities doctor is very excited about a new treatment for prostate cancer. The problem is he has to send people out of the country to get it. It's called Hifu.
http://www.redorbit.com/news/video/health/4/hifu_a_new_prostate_treatment/32155/index.html
Market cap of 55 million is ridiculous ..
anything below $5 is a gift
this stock will hit 10$ in no time with fda approval
test of 52w high coming
Load up edap while its still massive undervalued
4 approvals coming within the next 15 months
Market cap of 50 million is a big joke
EDAP is back on track to hit new highs
EDAP is a very very attractive investment .Their HIFU will be a big play in Cancer .
Time to buy more cheap shares
FDA approval is coming to push this low float monster to new highs .
APPROVAL NEWSSSSSSSS
US APPROVAL COMING SOON TOO
I think we could see 7$+ this Week .
EDAP read to Explode ..
Market cap : 55 M
Cash : 11 M
Price: 5 $
Shares Out : 11 M
Infos about HIFU
http://www.wjgnet.com/2218-4333/full/v2/i1/8.htm
http://www.cancercurecoalition.org/articles/hifu.htm
EDAP - On The Move
11/15/2010 6:25 AM ET
(RTTNews) - Shares of French medical device company EDAP TMS SA (EDAP: News ) have gained more than 30% over the past one week as the regulatory decision on its Sonolith i-move lithotripsy device for treatment of urinary tract stones draws closer.
The company submitted 510 (k) application for Sonolith i-move to the FDA on August 19, and is awaiting marketing clearance. Usually the FDA can clear or deny a 510(k) premarket notification within 90 days of submission of the application.
Sonolith i-move was approved in Europe in April of this year. Sonolith i-move is a compact, stand alone lithotripter with an infrared stereo-vision system for real-time, three-dimensional ultrasound localization of urinary stones.
Last August, the company's Sonolith i-sys, a predecessor to Sonolith i-move, received marketing clearance from the FDA, and in March of this year, won the regulatory approval in Japan.
In addition to lithotripsy devices, EDAP sells Ablatherm devices , a non-invasive treatment option, for localized prostate cancer. Ablatherm, a Class III device, which uses HIFU (High Intensity Focused Ultrasound), is currently approved in Europe, Canada, Russia, Australia and South East Asia. In the U.S., Ablatherm is undergoing multicenter phase II/III clinical trial under an Investigational Device Exemption granted by the FDA.
EDAP is also evaluating the HIFU technology in patients with metastatic liver cancer. Last month, the company successfully completed a preliminary trial of HIFU in liver cancer. Following the successful preliminary trial, the company has planned to conduct a second larger trial with the new HIFU device.
Buy on any dip this will move to 12$++ quickly .
Buy all you can at this ridiculous price . EDAP has the cancer answer .
This stock will move to 30$ and more in the coming months .
EDAP - On The Move
11/15/2010 6:25 AM ET
(RTTNews) - Shares of French medical device company EDAP TMS SA (EDAP: News ) have gained more than 30% over the past one week as the regulatory decision on its Sonolith i-move lithotripsy device for treatment of urinary tract stones draws closer.
The company submitted 510 (k) application for Sonolith i-move to the FDA on August 19, and is awaiting marketing clearance. Usually the FDA can clear or deny a 510(k) premarket notification within 90 days of submission of the application.
Sonolith i-move was approved in Europe in April of this year. Sonolith i-move is a compact, stand alone lithotripter with an infrared stereo-vision system for real-time, three-dimensional ultrasound localization of urinary stones.
Last August, the company's Sonolith i-sys, a predecessor to Sonolith i-move, received marketing clearance from the FDA, and in March of this year, won the regulatory approval in Japan.
In addition to lithotripsy devices, EDAP sells Ablatherm devices , a non-invasive treatment option, for localized prostate cancer. Ablatherm, a Class III device, which uses HIFU (High Intensity Focused Ultrasound), is currently approved in Europe, Canada, Russia, Australia and South East Asia. In the U.S., Ablatherm is undergoing multicenter phase II/III clinical trial under an Investigational Device Exemption granted by the FDA.
EDAP is also evaluating the HIFU technology in patients with metastatic liver cancer. Last month, the company successfully completed a preliminary trial of HIFU in liver cancer. Following the successful preliminary trial, the company has planned to conduct a second larger trial with the new HIFU device.
EDAP will explode if we break 5 dollar today .
Load up the cheap shares while its still very cheap
I told you so better get in before its too late.
EDAP will move like a hurricane